LIVIVO - Search results -

Search results

Result 1 - 10 of total 13

Search options

Article ; Online: Cost-effectiveness of long-term oxygen therapy for chronic obstructive disease.

Oba, Yuji

2009 Volume 15, Issue 2, Page(s) 97–104

Abstract: Objectives: To assess the cost-effectiveness of long-term oxygen therapy to facilitate proper ... for improvement in the current Medicare policies regarding long-term oxygen therapy. Medicare coverage can be ... improved by prescribing long-term oxygen therapy to patients who will receive substantial benefit and ...

Abstract	Objectives: To assess the cost-effectiveness of long-term oxygen therapy to facilitate proper resource allocation. Study design: Markov process. Methods: A Markov model was developed to estimate the incremental cost-effectiveness ratios (ICERs) for continuous and nocturnal oxygen therapies. The maximum time horizon was set to 5 years. Efficacy variables were obtained from pertinent clinical studies. Cost variables were based on the current Medicare reimbursement rate and on appropriate sources. Multiple 1-way and probabilistic sensitivity analyses were performed to examine the robustness of base-case results. Results: The ICER for continuous oxygen therapy ($16,124 per quality-adjusted life-year [QALY]) was within bounds considered to be cost-effective, while that of nocturnal oxygen therapy was not ($306,356/QALY). The estimated ICER for continuous oxygen therapy was robust (95% confidence interval, $13,153-$24,658/QALY) and was more favorable than the ICERs for commonly used medical and surgical therapies for chronic obstructive pulmonary disease. The ICER for nocturnal oxygen therapy was sensitive to variation in the mortality rate; it could be as low as $18,267/QALY gained. At the other end, nocturnal oxygen therapy could be less effective than no oxygen therapy, despite additional costs. Conclusions: There is substantial room for improvement in the current Medicare policies regarding long-term oxygen therapy. Medicare coverage can be improved by prescribing long-term oxygen therapy to patients who will receive substantial benefit and by providing adequate support for services and maintenance.
MeSH term(s)	Cost-Benefit Analysis/economics ; Humans ; Markov Chains ; Oxygen Inhalation Therapy/economics ; Pulmonary Disease, Chronic Obstructive/economics ; Pulmonary Disease, Chronic Obstructive/therapy
Language	English
Publishing date	2009-02
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2035781-3
ISSN	1936-2692 ; 1088-0224 ; 1096-1860
ISSN (online)	1936-2692
ISSN	1088-0224 ; 1096-1860
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5353: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 86: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Cost-Effectiveness of an Extended Home Visit Program for Oxygen-Dependent COPD Patients.

Lacasse, Yves / Bernard, Sarah / Maltais, François / Nguyen, Van Hung

Respiratory care

2022 Volume 67, Issue 9, Page(s) 1082–1090

Abstract: Background: Long-term oxygen therapy in COPD is usually supervised through home-care respiratory ... Conclusions: An extended home-visit program to maintain or improve adherence to long-term oxygen therapy ... oxygen therapy, followed by an extended follow-up period that aims toward home oxygen adherence ...

Abstract	Background: Long-term oxygen therapy in COPD is usually supervised through home-care respiratory programs. Such programs often involve an intensive education intervention at the initiation of long-term oxygen therapy, followed by an extended follow-up period that aims toward home oxygen adherence. The objective of this study was to estimate the cost-effectiveness ratio of such a maintenance program. Methods: A simulation model was developed that compared 2 strategies after the intensive education intervention: (1) enrollment and (2) no enrollment in a maintenance program. The study population consisted of a hypothetical cohort of 200 patients (100 patients per group; mean age, 74 years; 45% men; mean FEV Results: Over a 5-year period, an extended home-visit program may prevent 9 deaths and provide an additional 39 years of life and 24 quality-adjusted life-years. Compared with usual care (ie, no enrollment in the maintenance program), the incremental cost-effectiveness ratio was Can $17,197 per quality-adjusted life-years gained. Sensitivity analyses demonstrated the robustness of the model. Only a reduction in adherence of 25% per year would increase the incremental cost-effectiveness ratio per quality-adjusted life-years beyond the threshold of Can $50,000 that is usually considered as acceptable from a health-care system perspective. Conclusions: An extended home-visit program to maintain or improve adherence to long-term oxygen therapy in patients with COPD would most likely be cost-effective.
MeSH term(s)	Aged ; Canada ; Cost-Benefit Analysis ; Female ; House Calls ; Humans ; Male ; Oxygen ; Pulmonary Disease, Chronic Obstructive/therapy ; Quality of Life
Chemical Substances	Oxygen (S88TT14065)
Language	English
Publishing date	2022-06-21
Publishing country	United States
Document type	Journal Article
ZDB-ID	603252-7
ISSN	1943-3654 ; 0098-9142 ; 0020-1324
ISSN (online)	1943-3654
ISSN	0098-9142 ; 0020-1324
DOI	10.4187/respcare.09781
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2285: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Cost-Effectiveness of Humidified High-Flow Therapy (HHFT) for COPD Patients on Long-Term Oxygen Therapy.

Groessl, Erik J / Tally, Steven R / Hillery, Naomi

ClinicoEconomics and outcomes research : CEOR

2023 Volume 15, Page(s) 239–250

Abstract: ... therapy (HHFT) to standard long-term oxygen therapy (LTOT) as a home-based therapy in persons with severe ... Purpose: Chronic obstructive pulmonary disease (COPD) is the third leading cause of mortality, and ... COPD. The objective was to evaluate the cost-effectiveness of adding HHFT to standard treatment of COPD ...

Abstract	Purpose: Chronic obstructive pulmonary disease (COPD) is the third leading cause of mortality, and is associated with significant respiratory impairment, decreased quality of life, and high health care costs. Recent evidence indicates significant clinical benefit results from adding humidified high-flow therapy (HHFT) to standard long-term oxygen therapy (LTOT) as a home-based therapy in persons with severe COPD. The objective was to evaluate the cost-effectiveness of adding HHFT to standard treatment of COPD patients using LTOT with US healthcare cost estimates. Patients and methods: A Markov state-transition model was developed using data from a prospective clinical trial of adding HHFT to standard therapy for persons with severe COPD using LTOT. The analysis was conducted from the US health care system perspective using a 5-year time horizon and 3% discount rate. QALYs and downstream healthcare costs were modeled. One-way and probabilistic sensitivity analyses were used to examine the impact of input parameters on the incremental net monetary benefit (NMB). Results: Incremental QALYs accrued were 0.058 (2.047 vs 1.989 QALYs for HHFT and standard therapy groups respectively). Incremental total costs were -$3939 ($47,516 vs $51,455 for HHFT and standard therapy groups respectively). Thus, HHFT was the dominant treatment in the analysis, resulting on both better health and lower total costs. Varying utility and cost inputs individually never resulted in NMB approaching 0. Probabilistic analyses indicate that HHFT is cost-effective in 84% of simulations. Conclusion: Our results indicate that the reductions in acute exacerbations of COPD (AECOPDs) that result from adding HHFT for persons with COPD on LTOT will produce both health benefit (QALYs) and cost savings. Cost savings occur because the HHFT device costs are more than offset by reductions in costly COPD exacerbations. Health care systems and payors can benefit from wider implementation of HHFT with existing treatments.
Language	English
Publishing date	2023-04-05
Publishing country	New Zealand
Document type	Journal Article
ZDB-ID	2520698-9
ISSN	1178-6981
ISSN	1178-6981
DOI	10.2147/CEOR.S400739
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Cost-Effectiveness of Humidified High-Flow Therapy (HHFT) for COPD Patients on Long-Term Oxygen Therapy

Groessl EJ / Tally SR / Hillery N

ClinicoEconomics and Outcomes Research, Vol Volume 15, Pp 239-

2023 Volume 250

Abstract: ... clinical benefit results from adding humidified high-flow therapy (HHFT) to standard long-term oxygen ... therapy (LTOT) as a home-based therapy in persons with severe COPD. The objective was to evaluate the cost ... obstructive pulmonary disease (COPD) is the third leading cause of mortality, and is associated with significant respiratory ...

Abstract	Erik J Groessl,1,2 Steven R Tally,1 Naomi Hillery1 1Health Services Research Center, Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, CA, USA; 2VA San Diego Healthcare System, San Diego, CA, USACorrespondence: Erik J Groessl, University of California San Diego, Health Services Research Center, 9500 Gilman Drive, Mail Code 0994, San Diego, CA, 92037, USA, Tel +1 858 622 1771, Email egroessl@health.ucsd.eduPurpose: Chronic obstructive pulmonary disease (COPD) is the third leading cause of mortality, and is associated with significant respiratory impairment, decreased quality of life, and high health care costs. Recent evidence indicates significant clinical benefit results from adding humidified high-flow therapy (HHFT) to standard long-term oxygen therapy (LTOT) as a home-based therapy in persons with severe COPD. The objective was to evaluate the cost-effectiveness of adding HHFT to standard treatment of COPD patients using LTOT with US healthcare cost estimates.Patients and Methods: A Markov state-transition model was developed using data from a prospective clinical trial of adding HHFT to standard therapy for persons with severe COPD using LTOT. The analysis was conducted from the US health care system perspective using a 5-year time horizon and 3% discount rate. QALYs and downstream healthcare costs were modeled. One-way and probabilistic sensitivity analyses were used to examine the impact of input parameters on the incremental net monetary benefit (NMB).Results: Incremental QALYs accrued were 0.058 (2.047 vs 1.989 QALYs for HHFT and standard therapy groups respectively). Incremental total costs were -$3939 ($47,516 vs $51,455 for HHFT and standard therapy groups respectively). Thus, HHFT was the dominant treatment in the analysis, resulting on both better health and lower total costs. Varying utility and cost inputs individually never resulted in NMB approaching 0. Probabilistic analyses indicate that HHFT is cost-effective in 84% of ...
Keywords	copd ; acute exacerbations ; cost-effectiveness ; humidified high flow therapy ; Medicine (General) ; R5-920 ; Therapeutics. Pharmacology ; RM1-950
Subject code	610
Language	English
Publishing date	2023-04-01T00:00:00Z
Publisher	Dove Medical Press
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Cost-effectiveness of home non-invasive ventilation in COPD group GOLD D patients

BERES Enikő / BABES Katalin / BERES Zsolt-Levente / DAINA Lucia Georgeta / DAINA Cristian Marius / CHEREGI Cornel / CIUMARNEAN Lorena / DOGARU Gabriela

Balneo and PRM Research Journal, Vol 12, Iss 4, Pp 327-

2021 Volume 332

Abstract: ... guidelines and long-term oxygen therapy - LTOT vs. LTOT + NIV). We follow-up at 2 years with the study group ... Initiative for Chronic Obstructive Lung Disease) D patients generates supplementary costs, but the decreasing ... Introduction. Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and ...

Abstract	Introduction. Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality, estimated to be the third most common cause of death by 2020. The natural evolution of the disease is characterized by frequent exacerbations, severe exacerbations evolving with respiratory acidosis. Introducing home non-invasive ventilation (NIV) in the management of COPD group GOLD (Global Initiative for Chronic Obstructive Lung Disease) D patients generates supplementary costs, but the decreasing of the number of severe exacerbations will decrease the costs of drug treatment and hospitalization. This balance can be verified through a careful study of cost-effectiveness through modern methods of assessing the costs and years of life gained in relation to quality of life. Material and method. This prospective study took place in the Emergency Department of the Bihor County Clinical Emergency Hospital, Oradea, between 01 October 2017 – 31 October2018, with a follow-up period of 2 years. We included 36 Group risk D COPD patients, presented with severe exacerbation that required NIV; the patients were divided into two study groups according to the treatment scheme after discharge (standard medication according to GOLD guidelines and long-term oxygen therapy - LTOT vs. LTOT + NIV). We follow-up at 2 years with the study group, and analyze the following: number of exacerbations (moderate and severe), number of hospitalizations, mortality rate in two years, average costs for the treatment of exacerbations and for stable COPD periods, quality adjusted life year (QALY). Results and discussions. From 36 enrolled, 10 patients benefited from home NIV. The number of exacerbations was significantly lower in the NIV group compared with the LTOT group (1.72±0.79 vs 3.54±1.18). The incremental cost-effectiveness ratio (ICER) showed a net gain of 31% from gross product (GDP) per capita (5,641.71 ± 1,737.0-euro vs 9,272.3 ± 3,681.9 euro) per quality adjusted life year (QALY) for each patient. Conclusions. Introduction home-NIV ...
Keywords	chronic obstructive pulmonary disease ; non-invasive ventilation ; cost-effectiveness ; quality adjusted life year ; Science ; Q
Subject code	610
Language	English
Publishing date	2021-12-01T00:00:00Z
Publisher	Romanian Association of Balneology, Editura Balneara
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Cost-utility analysis of a telehealth programme for patients with severe chronic obstructive pulmonary disease treated with long-term oxygen therapy.

Jódar-Sánchez, Francisco / Ortega, Francisco / Parra, Carlos / Gómez-Suárez, Cristina / Bonachela, Patricia / Leal, Sandra / Pérez, Pablo / Jordán, Ana / Barrot, Emilia

Journal of telemedicine and telecare

2014 Volume 20, Issue 6, Page(s) 307–316

Abstract: ... with 45 patients treated with long-term oxygen therapy, 24 in the telehealth group (TG) and 21 ... obstructive pulmonary disease (COPD) compared with usual care. A randomized controlled trial was carried out over four months ... effectiveness ratio (ICER). The average total cost was €2300 for the TG and €1103 for the CG, and the average ...

Abstract	We conducted a cost-utility analysis of a telehealth programme for patients with severe chronic obstructive pulmonary disease (COPD) compared with usual care. A randomized controlled trial was carried out over four months with 45 patients treated with long-term oxygen therapy, 24 in the telehealth group (TG) and 21 in the control group (CG). The analysis took into account whether the severity of comorbidity (defined as the presence of additional chronic diseases co-occurring with COPD) was associated with differences in costs and/or quality-adjusted life years (QALYs). Results of cost-utility analysis were expressed in terms of the incremental cost-effectiveness ratio (ICER). The average total cost was €2300 for the TG and €1103 for the CG, and the average QALY gain was 0.0059 for the TG and 0.0006 for the CG (resulting an ICER of 223,726 €/QALY). For patients without comorbidity, the average total cost was €855 for the TG and €1354 for the CG, and the average QALY gain was 0.0288 for the TG and 0.0082 for the CG (resulting in the telehealth programme being the dominant strategy). For patients with comorbidity, the average total cost was €2782 for the TG and €949 for the CG, and the average QALY gain was -0.0017 for the TG and -0.0041 for the CG (resulting an ICER of 754,592 €/QALY). The telehealth programme may not have been cost-effective compared to usual care, although it could be considered cost-effective for patients without comorbidity.
MeSH term(s)	Aged ; Aged, 80 and over ; Cost-Benefit Analysis ; Female ; Health Care Costs ; Humans ; Male ; Middle Aged ; Outcome Assessment (Health Care) ; Oxygen Inhalation Therapy/economics ; Pilot Projects ; Program Evaluation ; Pulmonary Disease, Chronic Obstructive/therapy ; Quality-Adjusted Life Years ; Telemedicine/economics
Language	English
Publishing date	2014-09
Publishing country	England
Document type	Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	1340281-x
ISSN	1758-1109 ; 1357-633X
ISSN (online)	1758-1109
ISSN	1357-633X
DOI	10.1177/1357633X14544421
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4525: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Long-term air humidification therapy is cost-effective for patients with moderate or severe chronic obstructive pulmonary disease or bronchiectasis.

Milne, Richard J / Hockey, Hans / Rea, Harry

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

2014 Volume 17, Issue 4, Page(s) 320–327

Abstract: Objective: To establish the cost-effectiveness of long-term humidification therapy (LTHT) added ... to usual care for patients with moderate or severe chronic obstructive pulmonary disease or bronchiectasis ... Conclusions: LTHT is moderately cost-effective for patients with moderate to severe chronic ...

Abstract	Objective: To establish the cost-effectiveness of long-term humidification therapy (LTHT) added to usual care for patients with moderate or severe chronic obstructive pulmonary disease or bronchiectasis. Methods: Resource usage in a 12-month clinical trial of LTHT was estimated from hospital records, patient diaries, and the equipment supplier. Health state utility values were derived from the St. Georges Respiratory Questionnaire (SGRQ) total score. All patients who remained in the trial for 12 months and who had at least 90 days of diary records were included (87 of 108). Results: Clinical costs were NZ $3973 (95% confidence interval [CI] $1614-$6332) for the control group and NZ $3331 (95% CI $948-$6920) for the intervention group. The mean health benefit per patient was -6.9 SGRQ units (95% CI -13.0 to -7.2; P < 0.05) or +0.0678 quality-adjusted life-years (95% CI 0.001-0.135). With the intervention costing NZ $2059 annually, the mean cost per quality-adjusted life-year was NZ $20,902 (US $18,907) and the bootstrap median was NZ $19,749 (2.5th percentile -$40,923, 97.5th percentile $221,275). At a willingness-to-pay (WTP) threshold of NZ $30,000, the probability of cost-effectiveness was 61%, ranging from 49% to 72% as the cost of LTHT was varied by ±30%. At a WTP of NZ $20,000, the probability was 49% (range 34%-61%). Conclusions: LTHT is moderately cost-effective for patients with moderate to severe chronic obstructive pulmonary disease or bronchiectasis at a WTP threshold that is acceptable for public funding of medicines in New Zealand. These findings must be interpreted with caution because of the modest size of the clinical study, necessary lack of blinding in the clinical trial, and uncertainty in estimating health state utility from the SQRQ.
MeSH term(s)	Aged ; Bronchiectasis/economics ; Bronchiectasis/physiopathology ; Bronchiectasis/therapy ; Cost-Benefit Analysis ; Female ; Humans ; Humidity ; Male ; New Zealand ; Oxygen Inhalation Therapy/economics ; Oxygen Inhalation Therapy/methods ; Pulmonary Disease, Chronic Obstructive/economics ; Pulmonary Disease, Chronic Obstructive/physiopathology ; Pulmonary Disease, Chronic Obstructive/therapy ; Quality-Adjusted Life Years ; Severity of Illness Index ; Surveys and Questionnaires ; Treatment Outcome
Language	English
Publishing date	2014-06
Publishing country	United States
Document type	Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	1471745-1
ISSN	1524-4733 ; 1098-3015
ISSN (online)	1524-4733
ISSN	1098-3015
DOI	10.1016/j.jval.2014.01.007
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5904: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Cost-effectiveness and efficacy in long-term oxygen therapy.

Duck, Annette

Nursing times

2006 Volume 102, Issue 7, Page(s) 46–50

Abstract: ... of the potential hazards and benefits of oxygen therapy. Annette Duck reviews the use of long-term oxygen therapy ... Changes to the new home oxygen service have raised awareness among health professionals ...

Abstract	Changes to the new home oxygen service have raised awareness among health professionals of the potential hazards and benefits of oxygen therapy. Annette Duck reviews the use of long-term oxygen therapy and highlights the importance of assessment in selecting both patients and suitable delivery systems.
MeSH term(s)	Blood Gas Analysis ; Community Health Nursing/organization & administration ; Contract Services/organization & administration ; Cost of Illness ; Cost-Benefit Analysis ; Evidence-Based Medicine ; Home Care Services/organization & administration ; Humans ; Long-Term Care/economics ; Long-Term Care/standards ; Nurse's Role ; Nursing Assessment ; Oxygen/blood ; Oxygen Inhalation Therapy/economics ; Oxygen Inhalation Therapy/instrumentation ; Oxygen Inhalation Therapy/nursing ; Oxygen Inhalation Therapy/standards ; Patient Education as Topic ; Practice Guidelines as Topic ; Prescriptions/economics ; Prescriptions/standards ; Pulmonary Disease, Chronic Obstructive/blood ; Pulmonary Disease, Chronic Obstructive/mortality ; Pulmonary Disease, Chronic Obstructive/therapy ; State Medicine/organization & administration ; Survival Rate ; Treatment Outcome ; United Kingdom/epidemiology
Chemical Substances	Oxygen (S88TT14065)
Language	English
Publishing date	2006-02
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	391202-4
ISSN	0954-7762 ; 0029-6589
ISSN	0954-7762 ; 0029-6589
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 428: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MG 17: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis.

El-Serag, Hashem B / Graham, David Y / Richardson, Peter / Inadomi, John M

Archives of internal medicine

2002 Volume 162, Issue 18, Page(s) 2105–2110

Abstract: ... for patients requiring long-term treatment with NSAIDs to compare conventional NSAID therapy alone with 7 ... obstruction. Our objective in this study was to compare the cost-effectiveness of several strategies aimed ... with proton-pump inhibitor, cotherapy with misoprostol, cyclooxygenase [COX]-2-selective NSAID therapy, or ...

Abstract	Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with an increased risk of clinical upper gastrointestinal tract (UGI) events, namely, symptomatic ulcer, perforation, bleeding, and obstruction. Our objective in this study was to compare the cost-effectiveness of several strategies aimed at reducing the risk of clinical UGI events in NSAID users. Methods: A decision tree model was used for patients requiring long-term treatment with NSAIDs to compare conventional NSAID therapy alone with 7 other treatment strategies to reduce the risk of NSAID-related clinical UGI events (cotherapy with proton-pump inhibitor, cotherapy with misoprostol, cyclooxygenase [COX]-2-selective NSAID therapy, or Helicobacter pylori treatment followed by each of the previous strategies, including conventional NSAID treatment, respectively). The outcome measure is the incremental cost per clinical UGI event prevented compared with conventional NSAID treatment over 1 year. Results: The use of a COX-2-selective NSAID and cotherapy with proton-pump inhibitors were the 2 most cost-effective strategies. However, the incremental cost associated with these strategies was high (>$35 000) in persons with a low risk of clinical UGI event with conventional NSAIDs (eg, 2.5% per year). If the baseline risk of clinical UGI events is moderately high (eg, 6.5%), using a COX-2-selective NSAID becomes the most effective and least costly (dominant) treatment strategy, followed closely by cotherapy with a daily proton-pump inhibitor. Because small changes in costs or assumed efficacy of these drugs could change the conclusions, the incremental cost-effectiveness ratios between any 2 strategies were presented in a nomogram that allows the flexible use of a wide range of values for costs and rates of clinical UGI events. Conclusions: The risk of clinical UGI events in NSAID users depends on their baseline risk, the added risk associated with the individual NSAID, and the protection conferred by cotherapy. A nomogram can be used to incorporate these factors and derive estimates regarding cost-effectiveness of competing strategies aimed at reducing the risk of clinical UGI events.
MeSH term(s)	Anti-Inflammatory Agents, Non-Steroidal/adverse effects ; Anti-Inflammatory Agents, Non-Steroidal/economics ; Anti-Ulcer Agents/economics ; Anti-Ulcer Agents/therapeutic use ; Cost-Benefit Analysis ; Decision Support Techniques ; Drug Costs ; Health Care Costs ; Helicobacter Infections/drug therapy ; Helicobacter Infections/economics ; Humans ; Misoprostol/economics ; Misoprostol/therapeutic use ; Peptic Ulcer/chemically induced ; Peptic Ulcer/complications ; Peptic Ulcer/economics ; Peptic Ulcer/prevention & control ; Peptic Ulcer Hemorrhage/economics ; Peptic Ulcer Hemorrhage/etiology ; Peptic Ulcer Hemorrhage/prevention & control ; Peptic Ulcer Perforation/economics ; Peptic Ulcer Perforation/etiology ; Peptic Ulcer Perforation/prevention & control ; Primary Prevention/economics ; Proton Pump Inhibitors ; Risk Assessment ; Risk Factors ; United States
Chemical Substances	Anti-Inflammatory Agents, Non-Steroidal ; Anti-Ulcer Agents ; Proton Pump Inhibitors ; Misoprostol (0E43V0BB57)
Language	English
Publishing date	2002-10-14
Publishing country	United States
Document type	Journal Article ; Research Support, U.S. Gov't, Non-P.H.S.
ZDB-ID	211575-x
ISSN	1538-3679 ; 0003-9926 ; 0888-2479 ; 0730-188X
ISSN (online)	1538-3679
ISSN	0003-9926 ; 0888-2479 ; 0730-188X
DOI	10.1001/archinte.162.18.2105
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.119: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MA 14: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Pharmacoeconomic evaluation of the costs incurred by the ASP Messina for home therapy with liquid oxygen

Salvatore Coppolino

Farmeconomia: Health Economics and Therapeutic Pathways, Vol 11, Iss 1, Pp 43-

2010 Volume 46

Abstract: ... of therapy and patients survival can be obtained only by stopping smoking and by following a long term oxygen ... therapy. The aim of this retrospective study is to evaluate costs of liquid oxygen therapy performed ... Chronic obstructive pulmonary disease (COPD) is a very frequent disease ...

Abstract	Chronic obstructive pulmonary disease (COPD) is a very frequent disease in all industrialized countries. The cost for the community includes cost for hospitalisations, doctor visits, home care, rehabilitation, loss of working days, etc. From a therapeutical point of view, an effective progression of therapy and patients survival can be obtained only by stopping smoking and by following a long term oxygen therapy. The aim of this retrospective study is to evaluate costs of liquid oxygen therapy performed at home. Obtained results are very encouraging because a part from being cheap they also provide a better evaluation of the prescribed therapy which can also be extended to gaseous oxygen.
Keywords	copd ; oxygen therapy ; home care therapy ; Medicine (General) ; R5-920
Language	English
Publishing date	2010-03-01T00:00:00Z
Publisher	SEEd Medical Publishers
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED